Should ARDS definitions include HFNC/NIV and SpO₂/FiO₂—without overdiagnosing?
Abstract:
This narrative review contrasts the 2012 Berlin definition with newer proposals—including the Kigali modification and the emerging global definition—that broaden ARDS diagnosis to patients on HFNC/NIV, allow SpO₂/FiO₂ surrogates, and consider lung ultrasound (LUS) where ABGs or CXR/CT are limited; the authors welcome earlier recognition but caution about overdiagnosis, variability in imaging interpretation, and imprecision of SpO₂-based thresholds, and argue for a more nuanced framework that integrates physiology, lung-protective strategies, and candidate biomarkers (e.g., IL-6/IL-8/IFN-γ) to improve stratification and trial design.
Key Insights:
- What’s new: Proposals extend ARDS to non-intubated patients on HFNC ≥30 L/min or NIV/CPAP with PEEP ≥5 cmH₂O, using P/F ≤300 or SpO₂/FiO₂ ≤315 (if SpO₂ ≤97%) to avoid missing early injury.
- Severity bands (intubated): Mild 200<P/F≤300 (or 235<SpO₂/FiO₂≤315), Moderate 100<P/F≤200 (or 148<SpO₂/FiO₂≤235), Severe P/F≤100 (or SpO₂/FiO₂≤148) with PEEP ≥5.
- Kigali trade-offs: Allows SpO₂/FiO₂ and LUS and removes the PEEP requirement for resource-limited settings, but introduces operator dependence (LUS) and measurement noise (SpO₂).
- Risk of overdiagnosis: Broader criteria may capture non-ARDS hypoxemia; inter-observer variability and non-invasive oxygenation surrogates can blur specificity—standardized training and protocols are essential.
- Management anchors (ESICM 2023): VT 4–8 mL/kg PBW, Pplat ≤30, ΔP ≤15, individualized PEEP, proning (PaO₂/FiO₂<150), selective VV-ECMO, avoidance of routine recruitment maneuvers and continuous NMBA; consider awake proning and HFNC/NIV to avert intubation.
Why This Matters:
Earlier, more inclusive criteria can speed recognition and lung-protective care, but without rigor they risk diluting trial populations and misdirecting therapy—precision hinges on standardized imaging/oxygenation assessment plus physio/biomarker integration.
Conclusion:
Adopt expanded criteria judiciously: include HFNC/NIV and SpO₂/FiO₂ to catch ARDS earlier, but pair diagnosis with standardized imaging, physiologic targets, and biomarker-informed risk to preserve specificity and guide trials and care.
Take-Home for Clinicians:
Use the broadened thresholds to recognize ARDS sooner (especially on HFNC/NIV), then immediately align care to lung-protective ventilation, proning, and individualized PEEP; where ABGs/CXR are limited, deploy LUS and SpO₂/FiO₂ with training and protocolized interpretation to reduce noise, and consider biomarker panels as they mature to refine prognosis and trial referral.
Discussion Question: If your unit adopts HFNC/NIV-inclusive criteria, which standardized LUS and SpO₂/FiO₂ protocol will you use to maintain specificity and avoid overcalling ARDS?
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
